Ragosa Mark's Form 4 filing
Kiniksa Pharmaceuticals International, plc (KNSA) · filed Feb 11, 2026
- Accession no.
- 0001835458-26-000004
- Filed
- Feb 11, 2026
- Trade date
- Feb 9, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $772.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ragosa MarkCIK 0001835458 | Officer (CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +8,374 | $12.97 | +$108,610.78 | 27,460 | Direct | |
| Feb 9, 2026 | Class A Ordinary Share | MOption exerciseAcquired | +2,471 | $16.90 | +$41,759.9 | 29,931 | Direct | |
| Feb 9, 2026 | Class A Ordinary Share | SSaleDisposed | −9,114 | $42.85F2 | −$390,534.9 | 20,817 | Direct | |
| Feb 9, 2026 | Class A Ordinary Share | SSaleDisposed | −8,731 | $43.72F3 | −$381,719.32 | 12,086 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −8,374 | $0.00 | $0 | 0 | Direct | |
| Feb 9, 2026 | Class A Ordinary Share | MOption exerciseDisposed | −2,471 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $42.35 and $43.345. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.35 and $44.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.
Referenced by the price of 1 transaction in Table I.